IP Library Granted Patent US 12,520,840
Granted Patent B2
US 12,520,840 · App. 17/271,384 · Granted Jan 13, 2026

Method for reducing parasite burden in a mosquito

Inventors: Flaminia Catteruccia (Cambridge, MA); Douglas Graeme Paton (Cambridge, MA)
A01N35/06A01N37/42A01N43/60A61K9/0017A61K31/122A61K31/222A61K31/357A61K31/4192A61K31/495A61K31/505A61K47/12A61K47/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,520,840
App. No.
17/271,384
Granted
Jan 13, 2026
Kind
B2
Abstract

Described herein are methods and compositions for reducing transmission of Plasmodium to a female mosquito. Aspects of the invention relate to contacting to a mosquito with a Plasmodium transmission blocking compound. Another aspect of the invention relates to a surface coated with a Plasmodium transmission blocking compound.

Claims (10)

1 . A method for reducing transmission of Plasmodium to a female mosquito, the method comprising: contacting a female mosquito with a composition comprising an effective amount at least one Plasmodium transmission blocking compound, wherein the at least one Plasmodium transmission blocking compound is selected from the group consisting of atovaquone (ATQ), acequinocyl (ACE), and hydramethylnon (HYD), wherein the survival rate of the mosquito is not impacted by the contacting.

2 . The method of claim 1 , wherein the contacting comprises topical contacting or tarsal contacting.

3 . The method of claim 2 , wherein the tarsal contact comprises tarsal absorption or ingestion of the at least one Plasmodium transmission blocking compound, wherein the at least one Plasmodium transmission blocking compound is selected from the group consisting of atovaquone (ATQ), acequinocyl (ACE), and hydramethylnon (HYD).

4 . The method of claim 1 , wherein the contacting occurs on a surface coated with the at least one Plasmodium transmission blocking compound, wherein the at least one Plasmodium transmission blocking compound is selected from the group consisting of atovaquone (ATQ), acequinocyl (ACE), and hydramethylnon (HYD).

5 . The method of claim 4 , wherein the surface is selected from the group consisting of: an interior wall of a building; an exterior wall of a building; a bed net; an indoor fabric; an outdoor fabric; clothing; inside a trap; and outside a trap.

6 . The method of claim 1 , wherein reducing transmission inhibits the zygote/ookinete transition of Plasmodium development or in the inhibition of Plasmodium ookinete development.

7 . The method of claim 1 , wherein the female mosquito has been infected with Plasmodium prior to contacting.

8 . The method of claim 1 , wherein the composition further comprises at least one of a cuticular/tarsal uptake enhancer and a cytochrome P450 inhibitor.

9 . The method of claim 8 , wherein the cuticular/tarsal uptake enhancer comprises a mixture of the methyl esters of saturated and unsaturated C10-C26 fatty acids or rapeseed methyl ester.

10 . The method of claim 8 , wherein the cytochrome p450 inhibitor is at least one of piperonyl butoxide and 1-aminobenzotriazole.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 22, 2023
From: HARVARD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065664/0915 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2021
From: CATTERUCCIA, FLAMINIA; PATON, DOUGLAS GRAEME
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 055755/0666 →
Continuity (2)
Provisional Application 62726757 · Sep 4, 2018
Related Publication 20210330585A1 · Oct 28, 2021
References Cited (7)
US 20120115904A1 · Riscoe et al. · 2012 [cited by applicant]
US 20170022164A1 · Riscoe et al. · 2017 [cited by applicant]
US 20180213776A1 · Kakani et al. · 2018 [cited by applicant]
WO WO2014197703A1 · 2014 [cited by examiner]
WO WO2017015600A1 · 2017 [cited by examiner]
WO 2017222996A2 · 2017 [cited by applicant]
Stickles et al., “Inhibition of Cytochrome bc1 as a Strategy for Single-Dose, Multi-Stage Antimalarial Therapy”, Am. J. Trop. Med. Hyg., 92(6), 2015, pp. 1195-1201 (Year: 2015). [cited by examiner]